Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park, Isabelle Rivière, Mithat Gönen et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Life Sciences, Hematology, Oncology +17

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger et al. · Journal of Clinical Investigation · 2016 · 2.1K citations · Full text

Medicine, Immunology, Oncology +17

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

Brian G. Till, Michael C. Jensen, Jinjuan Wang et al. · Blood · 2008 · 719 citations · Full text

Life Sciences, Immunology, Oncology +17

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells

Paul E. Zarek, Ching-Tai Huang, Eric R. Lutz et al. · Blood · 2007 · 498 citations · Full text

Life Sciences, Genetics, Immunology +17